M2D Articles of Interest for Industry - 2026
Preamble
Large, integrated Clinical Research Organizations (CROs) with internal PV practices perform very well in specific situations. For example, they have established systems to handle enormous volumes of post-marketing cases, with strict automated processes that ensure timely compliance with global reporting rules. This setup ensures cost-effective case processing. These teams are staffed with professionals focused on the safety monitoring required of sponsors with both large product lines and high volumes, a sweet spot for the integrated CRO model. Their fantastic successes in this biopharma sector do not always translate to small, emerging biopharma organizations (SEBOs), and many SEBO leaders argue that the large, integrated CRO model is not ideal for clinical-stage, low-volume biopharma, where flexibility and quality are the main priorities.
Modern guidelines from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have placed a heavier oversight burden on sponsors. It is no longer acceptable to simply outsource safety tasks. Proactive monitoring is required because a "hands-off" approach carries significant regulatory risk. As a result, sponsors' successful compliance with these increased oversight requirements creates a dilemma for large, integrated CROs that can’t or have significant difficulty adapting to sponsors’ heightened oversight.
This dilemma presents significant challenges in navigating PV Departments within large, integrated CROs versus dedicated PV Service Providers. Integrated CROs have rigid, unforgiving structures and processes that create a host of PV deficiencies. These deficiencies engender enormous risks and costs for sponsors and their investors. These risks and costs are amplified exponentially for SEBOs.
The observed accelerating deterioration in the quality, regulatory compliance, and flexibility of PV Departments within large CROs over the past decade has highlighted the need for industry-wide awareness. It explicitly highlights their challenges or inability to adapt to the specific needs of SEBOs. Robust comparators exist. Specialized, dedicated PV service providers rapidly address issues that large CROs struggle with.
My role as an executive overseeing a life sciences consulting and advising firm for biopharma organizations of all sizes and stages in their lifecycle gives me extensive insight into the strengths and weaknesses of CRO relationships. The article reflects my formed opinion, and I fully recognize that some readers may not observe the similar traits described. This article explores the distinctions and proposes solutions to enhance the success of SEBO clinical programs. It is also a call to action, or at least elevates awareness, so we can all raise the bar on performance with our SEBO clients.
Large, integrated Clinical Research Organizations (CROs) with internal PV practices perform very well in specific situations. For example, they have established systems to handle enormous volumes of post-marketing cases, with strict automated processes that ensure timely compliance with global reporting rules. This setup ensures cost-effective case processing. These teams are staffed with professionals focused on the safety monitoring required of sponsors with both large product lines and high volumes, a sweet spot for the integrated CRO model. Their fantastic successes in this biopharma sector do not always translate to small, emerging biopharma organizations (SEBOs), and many SEBO leaders argue that the large, integrated CRO model is not ideal for clinical-stage, low-volume biopharma, where flexibility and quality are the main priorities.
Modern guidelines from the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have placed a heavier oversight burden on sponsors. It is no longer acceptable to simply outsource safety tasks. Proactive monitoring is required because a "hands-off" approach carries significant regulatory risk. As a result, sponsors' successful compliance with these increased oversight requirements creates a dilemma for large, integrated CROs that can’t or have significant difficulty adapting to sponsors’ heightened oversight.
This dilemma presents significant challenges in navigating PV Departments within large, integrated CROs versus dedicated PV Service Providers. Integrated CROs have rigid, unforgiving structures and processes that create a host of PV deficiencies. These deficiencies engender enormous risks and costs for sponsors and their investors. These risks and costs are amplified exponentially for SEBOs.
The observed accelerating deterioration in the quality, regulatory compliance, and flexibility of PV Departments within large CROs over the past decade has highlighted the need for industry-wide awareness. It explicitly highlights their challenges or inability to adapt to the specific needs of SEBOs. Robust comparators exist. Specialized, dedicated PV service providers rapidly address issues that large CROs struggle with.
My role as an executive overseeing a life sciences consulting and advising firm for biopharma organizations of all sizes and stages in their lifecycle gives me extensive insight into the strengths and weaknesses of CRO relationships. The article reflects my formed opinion, and I fully recognize that some readers may not observe the similar traits described. This article explores the distinctions and proposes solutions to enhance the success of SEBO clinical programs. It is also a call to action, or at least elevates awareness, so we can all raise the bar on performance with our SEBO clients.